Wealth Enhancement Advisory Services LLC Has $1.64 Million Position in STERIS plc (NYSE:STE)

Wealth Enhancement Advisory Services LLC raised its stake in STERIS plc (NYSE:STEFree Report) by 3.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,965 shares of the medical equipment provider’s stock after buying an additional 260 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in STERIS were worth $1,637,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Ashton Thomas Securities LLC acquired a new stake in shares of STERIS during the 3rd quarter valued at about $25,000. Central Pacific Bank Trust Division acquired a new stake in STERIS in the third quarter valued at approximately $28,000. Brown Brothers Harriman & Co. grew its position in STERIS by 154.7% in the second quarter. Brown Brothers Harriman & Co. now owns 191 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 116 shares in the last quarter. Quarry LP acquired a new position in shares of STERIS during the 3rd quarter worth $67,000. Finally, Asset Dedication LLC raised its holdings in shares of STERIS by 54.8% during the 3rd quarter. Asset Dedication LLC now owns 291 shares of the medical equipment provider’s stock valued at $71,000 after purchasing an additional 103 shares in the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. StockNews.com cut shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 29th. JMP Securities reiterated a “market outperform” rating and set a $265.00 price target on shares of STERIS in a research note on Monday, November 18th. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research note on Friday, November 8th. Piper Sandler raised STERIS from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $230.00 to $260.00 in a research report on Thursday, October 24th. Finally, Stephens reissued an “overweight” rating and issued a $260.00 price target on shares of STERIS in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $262.50.

Read Our Latest Stock Analysis on STERIS

STERIS Price Performance

Shares of NYSE:STE opened at $206.66 on Thursday. The company has a market cap of $20.40 billion, a price-to-earnings ratio of 47.18 and a beta of 0.84. The business has a 50 day moving average price of $212.34 and a 200 day moving average price of $224.89. The company has a quick ratio of 1.55, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. STERIS plc has a twelve month low of $197.82 and a twelve month high of $248.24.

STERIS (NYSE:STEGet Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, beating the consensus estimate of $2.12 by $0.02. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The company had revenue of $1.33 billion during the quarter, compared to analysts’ expectations of $1.33 billion. During the same period in the prior year, the business earned $2.03 earnings per share. STERIS’s revenue for the quarter was up 7.3% compared to the same quarter last year. Research analysts predict that STERIS plc will post 9.1 earnings per share for the current year.

STERIS Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th were issued a dividend of $0.57 per share. The ex-dividend date of this dividend was Tuesday, November 19th. This represents a $2.28 annualized dividend and a dividend yield of 1.10%. STERIS’s payout ratio is 52.05%.

Insider Activity

In other news, SVP Cary L. Majors sold 1,682 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $217.32, for a total transaction of $365,532.24. Following the sale, the senior vice president now directly owns 11,372 shares in the company, valued at approximately $2,471,363.04. The trade was a 12.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.14% of the stock is owned by company insiders.

STERIS Profile

(Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

See Also

Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STEFree Report).

Institutional Ownership by Quarter for STERIS (NYSE:STE)

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.